1. Akhtar N, Mikulic E, Cohn JN (1975) Hemodynamic effect of dobutamine in patients with severe heart failure. Am J Cardiol 36: 202–205
2. Angehrn W, Schmid E, Althaus F, Niedermann K, Rothlin M (1977) Leberdurchblutung unter Dopamin. Schweiz Med Wochenschr 107: 1593–1594
3. Assem ESK, Schild HO (1969) Inhibition by sympathomimetic amines of histamine release induced by antigen in the passively sensitized human lung. Nature 224: 1028–1029
4. Baving G, Ulmer WT (1970) Die Dosis-Wirkungs-Relation von peroral verabreichtem Orcipre- nalin bei obstruktiven Atemwegserkrankungen. Arzneimittelforsch 20: 1083–1088
5. Benedikter L, Mey T (1981) Onset and magnitude of cardiovascular response to dobutamine and AR-L115 B5, a new positive inotropic agent with additional vasodilating activity, in normal subj ects. Arzneimittelforsch 31: 239–242